Oppenheimer
Oppenheimer Downgrades Invitae to Perform Rating
Although Oppenheimer raised its price target from $48 to $51 in early January, the investment firm sees "increased risk of underperformance for Invitae shares."
Although the total number of deals went down in 2020, those deals were worth more compared to 2019 — four of the top five had billion-dollar price tags.
Oppenheimer Initiates Coverage of Bionano Genomics at Outperform
The investment bank said the company's molecular diagnostics have the potential to replace microarrays for cytogenetics analysis.
Bionano Genomics to Publicly Offer Securities, Amends Loan Agreement
The genome mapping firm had fallen out of compliance with respect to its loan agreement with Innovatus and will prepay $5 million toward the loan principal.
Bionano Genomics Prices $18M Public Offering
Shares of firm fell 47 percent on the news it will sell 20.9 million common shares along with warrants to purchase up to the same number of shares.